TPN

(redirected from Metabolic defects)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to Metabolic defects: Birth defects, Inborn errors of metabolism

TPN

abbr.
total parenteral nutrition

TPN

n
(Biochemistry) biochem triphosphopyridine nucleotide. a former name for NADP

TPN

total parenteral nutrition.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.TPN - administration of a nutritionally adequate solution through a catheter into the vena cavaTPN - administration of a nutritionally adequate solution through a catheter into the vena cava; used in cases of long-term coma or severe burns or severe gastrointestinal syndromes
alimentation, feeding - the act of supplying food and nourishment
Translations

TPN

abbr total parenteral nutrition. V. nutrition.
References in periodicals archive ?
Currently, liver transplantation is the only effective known treatment to correct the metabolic defects.
This observed mismatch between perfusion defects and metabolic findings and metabolic defects suggests the possibility of up-regulation of the glucose receptors to compensate for diminished perfusion.
17 Reagents for the Laboratory of Metabolic Defects, including the lease of the reader
Auxiliary liver transplant is proposed for liver-based metabolic defects that do not structurally damage the liver such as CNS I, urea cycle defects, and familial hypercholesterolaemia.
Vitamin C deficiencies and other metabolic defects have been suggested as possible causes of HOD, but no research to date supports this.
This research project should also investigate assessing those common genetic and metabolic defects that could render individuals even more susceptible to the harmful effects of lead.
We are just addressing the many metabolic defects and the natural history of diabetes.
In the study, the researchers used a high-resolution variant of fMRI to map metabolic defects in the brains of 96 adults enrolled in the Washington Heights-Inwood Columbia Aging Project (WHICAP).
The observed differences in therapeutic effectiveness and safety validate the strategy of initial triple therapy, namely, that it's better to target the insulin resistance and progressive beta-cell failure that constitute the core metabolic defects responsible for hyperglycemia and type 2 diabetes instead of simply focusing on lowering plasma glucose, added Dr.
The observed differences in therapeutic effectiveness and safety validate the strategy of targeting the insulin resistance and progressive beta cell failure that constitute the core metabolic defects responsible for hyperglycemia and type 2 diabetes, instead of focusing on lowering plasma glucose, added Dr.